Optimizing Pain Control in Transurethral Resection of the Prostate

Purpose

The purpose of this study is to develop a multi-modal protocol for pain management after TURP that minimizes opioid use. The investigators hypothesize this approach will provide non-inferior pain control to the current standard of care which includes opioids as the primary agent. The investigators believe this is an important step in reducing the opioid epidemic in surgical patients.

Conditions

  • Pain
  • BPH With Urinary Obstruction
  • BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Are identified as candidates for TURP - Are 18 years of age or greater - Are proficient in English

Exclusion Criteria

  • Have filled an opioid prescription in the last 2 months - Have an allergy to a medication included in the protocol - Have a history of pelvic radiation - Have renal failure (Serum Cr > 2.0 mg/dl), peptic ulcer disease, history of gastric bypass, cirrhosis, or other contraindication precluding use of NSAID's - Have liver failure, hepatitis, or alcohol abuse which precludes use of acetaminophen

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
No Intervention
Standard of care arm 		The standard of care group will group will receive the following regimen while inpatient: - 2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours - Acetaminophen 1000mg every 8 hours standing - Oxycodone 5mg PO every 4 hours as needed pain - Phenazopyridine 100mg TID as needed for urinary burning - Senna 1 tab every 12 hours - Miralax 17g powder once daily as needed for constipation The standard of care group will get the following prescriptions on discharge: - Oxycodone 5mg every 4 hours as needed pain - 15 tabs - Acetaminophen 1000mg every 8 hours standing for two days then as needed - Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs - Senna 1 tab every 12 hours - 10 tabs
Experimental
Multi-modal group 		The multi-modal group will receive the following regimen while inpatient: - 2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours - Acetaminophen 1000mg every 8 hours standing - Ibuprofen 600mg every 6 hours standing - Oxycodone 5mg PO every 4 hours as needed pain - Phenazopyridine 100mg TID as needed for urinary burning - Senna 1 tab every 12 hours - Miralax 17g powder once daily as needed for constipation - Patient Education (Figures 2 & 3) The multi-modal group will receive the following prescriptions on discharge: - Acetaminophen 1000mg every 8 hours standing for two days then as needed - 30 tabs - Ibuprofen 600mg every 8 hours standing for two days then as needed - 30 tabs - Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs - Senna 1 tab every 12 hours - 10 tabs
  • Drug: Ibuprofen 600 mg
    We'll be adding ibuprofen while trying to limit oxycodone use while hospitalized. Patients will not be discharged with a narcotic.
  • Behavioral: Education
    We'll be adding education to patient's post-operative instructions to aid in their pain control management.

Recruiting Locations

Virginia Mason Medical Center
Seattle 5809844, Washington 5815135 98101
Contact:
Ryan Donahue, MD
512-484-3214
ryan.donahue@vmmc.org

More Details

Status
Recruiting
Sponsor
Benaroya Research Institute

Study Contact

Ryan Donahue, MD
2062236600
ryan.donahue@vmmc.org

Detailed Description

In our study, the investigators will randomize TURP patients to standard of care versus a multi-modal protocol. Multi-modal pain control is defined as: "analgesia that combines 2 or more agents that act by different mechanisms to provide analgesia with better pain relief and less opioids". In addition, patients in the intervention arm will receive education regarding pain control and opioid use. The investigators aim to demonstrate non-inferior pain control with this approach. The investigators hope this will inform new guidelines for pain control after TURP, minimize opioid use in this patient population, and educate physicians and patients on providing excellent pain control while minimizing the risks of opioid use. The investigators believe this could ultimately serve as a model for other endoscopic urologic procedures as well.